D,l-cis-2,3-pyrrolidine Dicarboxylate Alters [3h]-l-glutamate Binding And Induces Convulsions In Mice

This study investigated whether D,L-cis-2,3-Pyrrolidine dicarboxylate (D,L-cis-2,3-PDC), a new glutamate analogue, alters glutamate binding to cerebral plasma membranes and whether N-methyl-D-aspartate (NMDA) receptors are involved in the convulsant effect of this compound. D,L-cis-2,3-PDC reduced sodium-independent [3H]-L-glutamate binding to lysed membrane preparations from adult rat cortex and had no effect on sodium-dependent glutamate binding. Intracerebroventricular administration of D,L-cis-2,3-PDC (7.5-25 nmol/5 μl) induced generalized tonic-clonic convulsions in mice in a dose-dependent manner. The coadministration of MK-801 (7 nmol/2.5 μl), with D,L-cis-2,3-PDC (16.5 nmol/2.5 μl), fully protected the animals against D,L-cis-2,3-PDC-induced convulsions, while the coadministration of DNQX (10 nmol/2.5 μl) increased the latency to convulsions but did not alter the percentage of animals that had convulsions. These results suggest that D,L-cis-2,3-PDC-induced effects are mediated predominantly by NMDA receptors. © 2003 Elsevier Inc. All rights reserved.762295299Bradford, M.M., A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding (1976) Anal. Biochem., 72, pp. 248-254Bridges, R.J., Stanley, M.S., Anderson, M.W., Cotman, C.W., Chamberlin, A.R., Conformationally defined neurotransmitter analogues. Selective inhibition of glutamate uptake by one pyrrolidine-2,4-dicarboxylate diasteroisomer (1991) J. Med. Chem., 34, pp. 717-725Carpes, M.J.S., Miranda, P.C.M.L., Correia, C.R.D., Stereoselective synthesis of conformationally restricted analogues of aspartic and glutamic acids from endocyclic enecarbamates (1997) Tetrahedron Lett., 38, pp. 1869-1872Chamberlin, A.R., Bridges, R.J., Conformationally constrained amino acids as probes of glutamate receptors and transporters (1993) Drug design for neuroscience, pp. 231-259. , A.P. Kozikowski. New York: RavenChoi, D.W., The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death (1990) Annu. Rev. Neurosci., 13, pp. 171-182Choi, D.W., Glutamate receptors and the induction of excitotoxic neuronal death (1994) Prog. Brain Res., 100, pp. 47-51Clark, W.G., Vivonia, C.A., Baxter, C.F., Accurate freehand injection into a lateral brain ventricle of the conscious mouse (1988) J. Appl. Physiol., 25, pp. 319-321Collingridge, G.L., Bliss, T.V.P., Memories of NMDA receptors and LTP (1995) Trends Neurosci., 18, pp. 54-56Conn, P.J., Patel, J., (1994) The metabotropic glutamate receptors, pp. 1-277. , Toyota (NJ): HumanaCotman, C.W., Kahle, J.S., Miller, S.E., Ulas, J., Bridges, R.J., Excitatory amino acid neurotransmission (1995) Psychopharmacology: The fourth generation of progress, pp. 75-85. , F.E. Bloom, & D.J. Kupfer. New York: Raven PressDaw, N.W., Stein, P.S., Fox, K., The role of NMDA receptors in information processing (1993) Annu. Rev. Neurosci., 16, pp. 207-222Debonnel, G., Beauchesne, L., Montigny, C., Domoic acid, the alleged "mussel toxin," might produce its neurotoxic effect through kainate receptor activation: An electrophysiological study in rat dorsal hippocampus (1989) Can. J. Physiol. Pharm., 67, pp. 29-33Emanuelli, T., Antunes, V.F., Souza, D.O.G., Characterization of L-[3H]glutamate binding to fresh and frozen crude plasma membranes isolated from cerebral cortex of adult rats (1998) Biochem. Mol. Biol. Int., 44, pp. 1265-1272Hollman, M., Heinemann, S., Cloned glutamate receptors (1994) Annu. Rev. Neurosci., 17, pp. 31-108Humphrey, J.M., Bridges, R.J., Chamberlin, A.R., 2,3-pyrrolidine dicarboxylates as neurotransmitter conformer mimics: Enantioselective synthesis via chelation-controlled enolate alkylation (1994) J. Org. Chem., 59, pp. 2467-2472Ishida, M., Shinozaki, H., Acromelic acid is a much more potent excitant than kainic acid or domoic acid in the rat spinal cord (1988) Brain Res., 474, pp. 386-389Kanai, Y., Smith, C.P., Hediger, M.A., The elusive transporters with a high affinity for glutamate (1993) Trends Neurosci., 16, pp. 365-370Kudo, Y., Akita, M., Ishida, M., Shinozaki, H., A significant increase in intracellular Ca2+ concentrations induced by (2S,3R,4S)-2-(carboxycyclopropyl)glycine, a new potent NMDA agonist, in cultured rat hippocampal neurons (1991) Brain Res., 567, p. 342Lanthorn, T.H., Hood, W.F., Watson, G.B., Compton, R.P., Rader, R.K., Gaoni, Y., Cis-2,4-Methanoglutamate is a potent and selective N-methyl-D-aspartate receptor agonist (1990) Eur. J. Pharmacol., 182, pp. 397-404Madsen, U., Bang-Andersen, B., Brehm, L., Christensen, I.T., Ebert, B., Kristoffersen, I.T.S., Synthesis and pharmacology of highly selective carboxy and phosphono isoxazole amino acid AMPA receptor antagonists (1996) J. Med. Chem., 39, pp. 1682-1691Meldrum, B.S., Excitotoxicity and selective neuronal loss in epilepsy (1993) Brain Pathol., 3, pp. 405-412Nakanishi, S., Metabotropic glutamate receptors: Synaptic transmission, modulation, and plasticity (1994) Neuron, 13, pp. 1031-1037Nicolletti, F., Bruno, V., Capani, A., Casabona, G., Knöpfel, T., Metabotropic glutamate receptors: A new target for the therapy of neurodegenerative disorders? (1996) Trends Neurosci., 19, pp. 267-271Ortwine, D.F., Malone, T.C., Bigge, C.F., Drummond, J.T., Humblet, C., Johnson, G., Generation of N-methyl-D-aspartate agonist and competitive antagonist pharmacophore models. Design and synthesis of phosphonoalkyl-substituted tetrahydroisoquinolines as novel antagonists (1992) J. Med. Chem., 35, pp. 1345-1370Racine, R.J., Modification of seizure activity by electrical stimulation: II. Motor seizure (1972) Electroenceph. Clin. Neurophysiol., 32, pp. 281-294Rao, R., Murthy, R.K., Characteristics of [3H] glutamate binding sites in rat cerebellum (1993) Biochem. Mol. Biol. Int., 30, pp. 861-866Rothman, S.M., Olney, J.W., Excitotoxicity and the NMDA receptor-still lethal after eight years (1995) Trends Neurosci., 18, pp. 57-58Schoepp, D.D., Smith, C.L., Lodge, D., Millar, J.D., Leander, J.D., Sacaan, A.I., D,L-(tetrazol-5-yl)glycine: A novel and highly potent NMDA receptor agonist (1991) Eur. J. Pharmacol., 203, pp. 237-243Schoepp, D.D., Lunn, W.H.W., Salhoff, C.R., McDonald, J.W., The NMDA receptor agonist D,L-(tetrazol-5-yl)glycine is a highly potent excitotoxin (1994) Eur. J. Pharmacol., 270, pp. 67-72Shinozaki, H., Ishida, M., Shimamoto, K., Ohfune, Y., A conformationally restricted analogue of L-glutamate, the (2S,3R,4S) isomer of L-α-(carboxycyclopropyl)glycine, activates the NMDA-type receptor more markedly than NMDA in the isolated rat spinal cord (1989) Brain Res., 480, pp. 355-359Szatkowski, M., Attwell, D., Triggering and execution of neuronal death in brain ischaemia: Two phases of glutamate release by different mechanisms (1994) Trends Neurosci., 17, pp. 359-365Watkins, J.C., Krogsgaard-Larsen, P., Honore, T., Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists (1990) Trends Pharmacol. Sci., 11, pp. 25-33Willis, C.L., Humphrey, J.M., Koch, H.P., Blakely, T., Ralston, L., Baker, C.A., L-Trans-2,3-pyrrolidine dicarboxylate: Characterization of a novel excitotoxin (1996) Neuropharmacology, 35, pp. 531-539Willis, C.L., Dauenhauer, D.L., Humphrey, J.M., Chamberlin, A.R., Buller, A.L., Monaghan, D.T., Methylation of the NMDA receptor agonist L-trans-2,3-pyrrolidine- dicarboxylate: Enhanced excitotoxic potency and selectivity (1997) Toxicol. Appl. Pharmacol., 144, pp. 45-5

Antinociceptive effect of novel pyrazolines in mice

The antinociceptive effect of six novel synthetic pyrazolines (3-ethoxymethyl-5-ethoxycarbonyl-1H-pyrazole (Pz 1) and its corresponding 1-substituted methyl (Pz 2) and phenyl (Pz 3) analogues, and 3-(1-ethoxyethyl)-5-ethoxycarbonyl-1H-pyrazole (Pz 4) and its corresponding 1-substituted methyl (Pz 5) and phenyl (Pz 6) analogues) was evaluated by the tail immersion test in adult male albino mice. The animals (N = 11-12 in each group) received vehicle (5% Tween 80, 10 ml/kg, sc) or 1.5 mmol/kg of each of the pyrazolines (Pz 1-Pz 6), sc. Fifteen, thirty and sixty minutes after drug administration, the mice were subjected to the tail immersion test. Thirty minutes after drug administration Pz 2 and Pz 3 increased tail withdrawal latency (vehicle = 3.4 ± 0.2; Pz 2 = 5.2 ± 0.4; Pz 3 = 5.9 ± 0.4 s; mean ± SEM), whereas the other pyrazolines did not present antinociceptive activity. Dose-effect curves (0.15 to 1.5 mmol/kg) were constructed for the bioactive pyrazolines. Pz 2 (1.5 mmol/kg, sc) impaired motor coordination in the rotarod and increased immobility in the open-field test. Pz 3 did not alter rotarod performance and spontaneous locomotion, but increased immobility in the open field at the dose of 1.5 mmol/kg. The involvement of opioid mechanisms in the pyrazoline-induced antinociception was investigated by pretreating the animals with naloxone (2.75 µmol/kg, sc). Naloxone prevented Pz 3- but not Pz 2-induced antinociception. Moreover, naloxone pretreatment did not alter Pz 3-induced immobility. We conclude that Pz 3-induced antinociception involves opioid mechanisms but this is not the case for Pz 2

A pyrazolyl-thiazole derivative causes antinociception in mice

The present study investigates the antinociceptive effect of the pyrazolyl-thiazole derivative 2-(5-trichloromethyl-5-hydroxy-3-phenyl-4,5-dihydro-1 H-pyrazol-1-yl)-4-(4-bromophenyl)-5-methylthiazole (B50) in mice. Male albino Swiss mice (30-40 g) were used in the acetic acid-induced abdominal writhes and tail-immersion tests. B50 caused dose-dependent antinociception (8, 23 and 80 µmol/kg, sc) in the acetic acid writhing assay (number of writhes: vehicle: 27.69 ± 6.15; B50 (8 µmol/kg): 16.92 ± 3.84; B50 (23 µmol/kg): 13.85 ± 3.84; B50 (80 µmol/kg): 9.54 ± 3.08; data are reported as means ± SEM for 9 animals per group). On the other hand, B50 did not cause antinociception in the tail immersion assay. Naloxone (2.75 µmol/kg, sc) prevented B50-induced antinociception (number of writhes: vehicle-saline: 31.11 ± 3.15; vehicle-naloxone: 27.41 ± 3.70; B50 (80 µmol/kg)-saline: 8.70 ± 3.33; B50 (80 µmol/kg)-naloxone: 31.84 ± 4.26; morphine-saline: 2.04 ± 3.52; morphine-naloxone: 21.11 ± 4.26; 8-9 animals per group). The removal of the methyl group of the thiazole ring of B50 or substitution of the bromo substituent with the methyl at position 4 of the phenyl group, which is attached to the thiazole ring of B50, resulted in loss of activity, suggesting that these substituents are important for antinociceptive activity. B50 had no effect on spontaneous locomotion or rotarod performance, indicating that the antinociceptive effect of B50 is not related to nonspecific motor effects. The antinociceptive profile of B50 seems to be closer to nonsteroidal anti-inflammatory drugs than to classic opioid agents, since it had no analgesic effect in a thermally motivated test

Antinociceptive effects of Cremophor EL orally administered to mice

Surfactants are frequently used to improve solubilization of lipophilic drugs. Cremophor EL (CrEL) is a polyoxyethylated castor oil surfactant used to solubilize water-insoluble drugs such as anesthetic, antineoplastic, immunosuppressive and analgesic drugs, vitamins and new synthetic compounds, including potential analgesics. The antinociceptive effect of CrEL (3.2, 6.4 and 10.6 g/kg, in 10 ml/kg body weight, by gavage) on the abdominal writhing response induced by intraperitoneal administration of acetic acid (0.8%, 10 ml/kg body weight) and on the tail immersion test was investigated in mice. Control animals received castor oil (10 ml/kg body weight) or saline (0.9% NaCl, 10 ml/kg body weight). CrEL reduced nociception in a dose-dependent manner in both tests. At 10.6 g/kg, CrEL caused antinociception similar to that induced by dipyrone (300 mg/kg, by gavage) in the abdominal writhing test, and antinociception similar to that induced by morphine (20 mg/kg, by gavage) in the tail immersion test. The effect of castor oil was similar to that of saline in both assays. These data indicate that the appropriate controls should be used when evaluating the effects of potential antinociceptive agents dissolved in CrEL